Kenvue stock rebounds: Tylenol maker rises 6Żter Donald Trumpâs autism claims; analysts see limited legal impact
Kenvue stock rebounds: Tylenol maker rises 6Żter Donald Trumpâs autism claims; analysts see limited legal impact
Kenvue shares rebounded after a sharp fall triggered by Donald Trump's unfounded claims linking Tylenol to autism. Trump advised pregnant women to avoid the drug, despite a lack of new scientific evidence. Kenvue refuted the claims, while an analyst predicted limited lawsuit risks but cautioned about potential consumption decline due to negative publicity.
Kenvue shares rebounded after a sharp fall triggered by Donald Trump's unfounded claims linking Tylenol to autism. Trump advised pregnant women to avoid the drug, despite a lack of new scientific evidence. Kenvue refuted the claims, while an analyst predicted limited lawsuit risks but cautioned about potential consumption decline due to negative publicity.
Kenvue shares rebounded after a sharp fall triggered by Donald Trump's unfounded claims linking Tylenol to autism. Trump advised pregnant women to avoid the drug, despite a lack of new scientific evidence. Kenvue refuted the claims, while an analyst predicted limited lawsuit risks but cautioned about potential consumption decline due to negative publicity. 
